Age-Related Macular Degeneration

Company announces reimbursement terms for Macugen

Published in Medical Letter on the CDC and FDA, March 13th, 2005

Eyetech Pharmaceuticals, Inc., (EYET) announced that the U.S. Centers for Medicare & Medicaid Services has posted effective January 1, 2005, that the Medicare part B allowable for Macugen (pegaptanib sodium injection) is 106% of average sales price or $1054.70 per injection.

Macugen was approved by the U.S. Food and Drug Administration on December 17, 2004 for use in the treatment of neovascular (wet) age-related macular degeneration (AMD), an eye disease associated with aging that destroys central vision.

Eyetech and Pfizer launched Macugen on January 20, 2005.

Eyetech is a biopharmaceutical company that specializes in the...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Medical Letter on the CDC and FDA

Source: Medical Letter on the CDC and FDA (2005-03-13)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry

Search our medical news database